Search research articles
Contact Us
Filters
Showing results (201-210 of 215) with videos related to
Page
of 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2026
Distinct malignant cell states and myeloid glutamate signaling associated with aggressive pancreatic neuroendocrine tumors
Jeanna M Arbesfeld-Qiu, Jae-Won Cho, Phuong T T Nguyen, et al.
Nature Communications
|
November 10, 2024
Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia
Irina Arnaoutova, Yvonne Aratyn-Schaus, Lisa Zhang, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 30, 2015
Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup
Pratik Devasthale, Wei Wang, Andres S Hernandez, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 21, 2015
Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies
Pratik Devasthale, Wei Wang, James Mignone, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2022
Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
Matthew D Hill, Haiquan Fang, Derek Norris, et al.
The American Journal of Surgical Pathology
|
April 21, 2026
Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer
Fahad Khan, Alexandros D Polydorides, John D Paulsen, et al.
Journal of Medicinal Chemistry
|
September 11, 2014
Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119
Dean A Wacker, Ying Wang, Matthias Broekema, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 11, 2011
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1)
Shung C Wu, David Yoon, Janice Chin, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 18, 2015
Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists
Hao Zhang, Charles Z Ding, Zhi Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2025
Therapeutic Targeting of Epithelial Mesenchymal Cellular Plasticity in Pancreatic Cancer
Eric W Lin, Priyadarshini Pathak, Aileen O'Shea, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 215) with videos related to
Sort By:
Page
of 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2026
Distinct malignant cell states and myeloid glutamate signaling associated with aggressive pancreatic neuroendocrine tumors
Jeanna M Arbesfeld-Qiu, Jae-Won Cho, Phuong T T Nguyen, et al.
Nature Communications
|
November 10, 2024
Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia
Irina Arnaoutova, Yvonne Aratyn-Schaus, Lisa Zhang, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 30, 2015
Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup
Pratik Devasthale, Wei Wang, Andres S Hernandez, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 21, 2015
Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies
Pratik Devasthale, Wei Wang, James Mignone, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2022
Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
Matthew D Hill, Haiquan Fang, Derek Norris, et al.
The American Journal of Surgical Pathology
|
April 21, 2026
Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer
Fahad Khan, Alexandros D Polydorides, John D Paulsen, et al.
Journal of Medicinal Chemistry
|
September 11, 2014
Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119
Dean A Wacker, Ying Wang, Matthias Broekema, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 11, 2011
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1)
Shung C Wu, David Yoon, Janice Chin, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 18, 2015
Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists
Hao Zhang, Charles Z Ding, Zhi Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2025
Therapeutic Targeting of Epithelial Mesenchymal Cellular Plasticity in Pancreatic Cancer
Eric W Lin, Priyadarshini Pathak, Aileen O'Shea, et al.
Page
of 22